Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
TEL AVIV, Israel and WHITE PLAINS, N.Y., May 9, 2013 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today that its wholly owned subsidiary, Orgenesis Ltd., has entered into a process development agreement (the “PD Agreement”) with ATMI, Inc. (Nasdaq:ATMI), a global technology company and leader in single-use bioprocess solutions.
Help employers find you! Check out all the jobs and post your resume.
